Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Audio-Visual Consent Recording in India – V 2.0

Posted on By

BA-BE Studies: SOP for Audio-Visual Consent Recording in India – V 2.0

Standard Operating Procedure for Audio-Visual Consent Recording in India for BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/024/2025
Supersedes SOP/BA-BE/024/2022
Page No. Page 1 of 13
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for conducting, documenting, and storing audio-visual (AV) recordings of the informed consent process for BA/BE studies conducted in India, as per the requirements of the CDSCO and Indian regulatory authorities.

2. Scope

This SOP applies to all BA/BE studies involving human participants in India where audio-visual recording of the informed consent process is mandated as per GSR 611(E) notification and Schedule Y guidelines.

3. Responsibilities

  • Investigator: Conducts the AV consent session and ensures participant understanding.
  • Clinical Staff/Nurse: Coordinates logistics and manages recording equipment.
  • Regulatory Affairs: Ensures process compliance and storage requirements are met.
  • IT/AV Technician: Assists in setup, testing, and file management of recordings.
See also  BA-BE Studies: SOP for Preparing Product-Specific Guidance Review Summary - V 2.0

4. Accountability

The Principal Investigator is accountable for the ethical and regulatory compliance of the AV consent process and the secure storage of recordings for the retention period.

5. Procedure

5.1 Preparation for AV Recording

  1. Identify private and quiet space with good lighting and audio conditions.
  2. Ensure backup recording device is available (in case of failure).
  3. Use Annexure-1: AV Consent Equipment Checklist to verify readiness.

5.2 Conduct of AV Consent

  1. Begin recording and introduce all participants in the frame:
    • Participant
    • Investigator
    • Witness (if participant is illiterate)
  2. Explain:
    • Study objective, duration, and procedures
    • Risks and benefits
    • Right to withdraw
    • Compensation policy
  3. Encourage questions and record verbal consent from the participant.
  4. Document that the participant voluntarily agrees to participate.

5.3 Consent Documentation

  1. After AV recording, obtain participant’s signature on physical ICF.
  2. Record the AV file ID on the signed ICF and log it in Annexure-2: AV Consent Master Log.
See also  BA-BE Studies: SOP for Archival of Regulatory Correspondence - V 2.0

5.4 File Storage and Backup

  1. Label the AV file using unique subject ID and date (e.g., BE031_SUB001_170425.mp4).
  2. Store files securely in encrypted folders with restricted access.
  3. Create backup in a validated external drive or server location.
  4. Retain files for a minimum of 5 years or as per sponsor/GCP requirements.

5.5 Audit and Review

  1. Ensure availability of files for EC, CDSCO, or sponsor audit when requested.
  2. Review recordings quarterly for quality checks as per Annexure-3: AV Quality Review Log.

6. Abbreviations

  • AV: Audio-Visual
  • ICF: Informed Consent Form
  • EC: Ethics Committee
  • CDSCO: Central Drugs Standard Control Organization
  • PI: Principal Investigator

7. Documents

  1. AV Consent Equipment Checklist – Annexure-1
  2. AV Consent Master Log – Annexure-2
  3. AV Quality Review Log – Annexure-3

8. References

  • Schedule Y – Drugs and Cosmetics Rules
  • GSR 611(E), 2014 – Audio-Visual Consent Guidelines
  • ICMR National Ethical Guidelines, 2017
  • ICH E6(R2) – Good Clinical Practice
See also  BA-BE Studies: SOP for Risk Assessment of Study Protocol in BA/BE Studies - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: AV Consent Equipment Checklist

Item Status Remarks
Camera (HD) Available Functional
Microphone Available Clear audio
Lighting Installed Adjusted

Annexure-2: AV Consent Master Log

Subject ID Study Code Date File Name Stored Location
SUB001 BE-035 17/04/2025 BE035_SUB001_170425.mp4 Drive A/Site Folder

Annexure-3: AV Quality Review Log

Date Reviewed Reviewed By Subject IDs Reviewed Remarks
30/04/2025 QA Reviewer SUB001, SUB002 Clear audio and visibility

Revision History:

Revision Date Revision No. Details Reason Approved By
12/01/2022 1.0 Initial SOP New CDSCO mandate QA Head
17/04/2025 2.0 Added Annexures and enhanced AV compliance measures Regulatory alignment QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Tablets: SOP for Review and Approval of Process Deviations – V 2.0
Next Post: Capsule: SOP for Labeling Bottled Capsules – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version